Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

CARLSBAD, Calif., June 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the fourth and last of this series of conference calls focused on the drugs in Isis' development pipeline.  The last call of the series will focus on Isis' neurodegenerative franchise and will be held on Thursday, June 17, 2010 at 12:00 p.m. ET.  This call will be archived for a limited time on Isis' Web site.

Isis has conducted three earlier calls that highlighted its cardiovascular, metabolic and cancer franchises.  The last call of the series will focus on Isis' neurodegenerative franchise as well as some of the other promising programs Isis and its partners are developing.  

Conference Call

At 12:00 p.m. Eastern Time Thursday, June 17, 2010, Isis will conduct a live webcast conference call.  Interested parties may listen to the call by dialing 866-831-6247 and refer to passcode "ISIS 2010" or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.  

Isis' Neurodegenerative Franchise

Isis is pursuing the discovery and development of antisense drugs for neurodegenerative diseases in which there is a large unmet need for new treatment options.  Isis' initial goal is to develop ant
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... DIEGO , April 21, 2015 ... design and development, custom automation, and contract manufacturing, ... and accessible flow cytometry and cell sorting technology ... to develop a novel flow cytometry platform. ... , NanoCellect Biomedical has developed a microchip-based cell ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... announced that its Board of Directors has elected ... of the Transaction and Pricing Committee, with oversight on ... a member of the Audit Committee, the Compensation Committee ... Upon his election, Mr. Azria commented: "I have a ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading provider ... Josh Forsythe as VP of Marketing. Mr. Forsythe ... a significant expansion in its commercial operations over the last ... " Josh Forsythe is a tremendous addition to ... MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing software ...
Breaking Biology Technology:AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... Phase 1 clinical studies support advancement to Phase 2 ... Roche polymerase inhibitors -, BRISBANE, Calif., Sept. 24 ... four abstracts from clinical and,in-vitro studies of ITMN-191 (R7227) ... American Association for the Study of Liver Diseases,(AASLD, Oct. ...
... new screening platform for antibody therapeutics, BASEL, ... today that it has completed the acquisition of ... of ARIUS Research (TSX: ARI). On,September 19th, the ... previously approved by the security holders and announced ...
... signing to follow his presentation, WASHINGTON, Sept. ... global marketplace, and the role of,financing are focus ... presentations will focus on the convergence of the,MedTech ... patient monitoring,technologies, critical issues to consider when entering ...
Cached Biology Technology:InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6Roche completes acquisition of ARIUS 2Former Speaker of the House Newt Gingrich Featured Wednesday 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... upcoming paper from Dr. David Wassarman (University of Wisconsin ... 1 issue of G&D lends new insight into the ... (A-T) is a rare, genetic immunodeficiency disease that affects ... cancer predisposition. A-T is caused by recessive mutations in ...
... to designing something, its hard to find a better ... principle, a diverse, interdisciplinary group of researchers at the ... to synthesize magnetic nanoparticles that could be used for ... high-density memory devices, or as magnetic seals in motors. ...
... nature vs. nurture debate is familiar to most people, ... two. A new paper published this week in the ... similar balance between the genes we inherit—nature—and the environment—nurture—in ... the age of personal genomics, in which each of ...
Cached Biology News:Researchers mimic bacteria to produce magnetic nanoparticles 2Researchers mimic bacteria to produce magnetic nanoparticles 3
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Biology Products: